{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:23:54Z","timestamp":1787315034716,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Patolog\u00eda"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.patol.2026.100873","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:50:20Z","timestamp":1778190620000},"page":"100873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer"],"prefix":"10.1016","volume":"59","author":[{"given":"Pilar","family":"Gonz\u00e1lez-Peramato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Garc\u00eda-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jambrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Freire","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Hern\u00e1ndez-Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Linares-Espin\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.patol.2026.100873_bib0255","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.patol.2026.100873_bib0260","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","article-title":"Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in brca2 mutation carriers with prostate cancer and correlates with poor prognosis","volume":"67","author":"Risbridger","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.patol.2026.100873_bib0265","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.patol.2026.100873_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.patol.2026.100873_bib0275","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1056\/NEJMc2023199","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"383","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2026.100873_bib0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2026.100873_bib0285","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0290","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0295","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1464-410x.2000.00457.x","article-title":"Hereditary prostate cancer","volume":"85","author":"Bratt","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.patol.2026.100873_bib0300","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/1078-0432.CCR-08-1822","article-title":"Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations","volume":"15","author":"Agalliu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.patol.2026.100873_bib0305","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0310","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.patol.2026.100873_bib0315","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"Prorepair-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0320","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.patol.2026.100873_bib0505","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet."},{"key":"10.1016\/j.patol.2026.100873_bib0330","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0335","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2024","journal-title":"Semin Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0340","unstructured":"NCCN. NCCN clinical practice guidelines in onclogy: prostate cancer v1.2025. n.d."},{"key":"10.1016\/j.patol.2026.100873_bib0345","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid, Spain 2025. ISBN 978-94-92671-29-5. n.d."},{"key":"10.1016\/j.patol.2026.100873_bib0510","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol."},{"key":"10.1016\/j.patol.2026.100873_bib0355","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0360","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12094-021-02561-5","article-title":"SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)","volume":"23","author":"Gonz\u00e1lez del Alba","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cjp2.203","article-title":"Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer","volume":"7","author":"Gonzalez","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.patol.2026.100873_bib0370","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.7954","article-title":"Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada","volume":"16","author":"Selvarajah","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.patol.2026.100873_bib0375","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2022.01.006","article-title":"Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing","volume":"33","author":"Terraf","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0380","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0385","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2026.100873_bib0390","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.patol.2026.100873_bib0395","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00195","article-title":"Genomic biomarkers and genome-wide loss-of-heterozygosity scores in metastatic prostate cancer following progression on androgen-targeting therapies","author":"Zurita","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0400","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.patol.2026.100873_bib0405","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Erratum: integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.patol.2026.100873_bib0410","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2021.2350","article-title":"Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA","volume":"7","author":"Schweizer","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0415","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.patol.2026.100873_bib0420","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/PAT.0000000000000183","article-title":"Optimising pre-analytical factors affecting quality of prostate biopsies: the case for site specific labelling and single core submission","volume":"46","author":"Srigley","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.patol.2026.100873_bib0425","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.celrep.2018.10.046","article-title":"Reliability of whole-exome sequencing for assessing intratumor genetic heterogeneity","volume":"25","author":"Shi","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.patol.2026.100873_bib0430","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/modpathol.2016.116","article-title":"Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer","volume":"29","author":"Schrijver","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.patol.2026.100873_bib0435","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.patol.2026.100873_bib0440","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jmoldx.2016.09.006","article-title":"Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine","volume":"19","author":"Kim","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.patol.2026.100873_bib0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.prnil.2022.07.002","article-title":"Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: a nationwide survey and calibration project in China","volume":"10","author":"Wu","year":"2022","journal-title":"Prostate Int"},{"key":"10.1016\/j.patol.2026.100873_bib0450","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","article-title":"Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial","volume":"19","author":"Lih","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.patol.2026.100873_bib0455","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5584-6","article-title":"Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples","volume":"19","author":"Zakrzewski","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.patol.2026.100873_bib0460","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3343\/alm.2023.43.1.64","article-title":"Comparison of homologous recombination repair gene next-generation sequencing analysis in patients with metastatic castration-resistant prostate cancer between local and central laboratories in Korea","volume":"43","author":"Kim","year":"2023","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.patol.2026.100873_bib0465","series-title":"Genomics in the cloud: using Docker, GATK, and WDL in Terra","author":"Van der Auwera","year":"2020"},{"key":"10.1016\/j.patol.2026.100873_bib0470","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.patol.2026.100873_bib0475","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/gim.2018.42","article-title":"The ACMG\/AMP reputable source criteria for the interpretation of sequence variants","volume":"20","author":"Biesecker","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.patol.2026.100873_bib0480","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.patol.2026.100873_bib0485","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.patol.2026.100873_bib0490","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.patol.2026.100873_bib0495","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2026.100873_bib0500","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.annonc.2024.06.018","article-title":"ESMO Recommendations on clinical reporting of genomic test results for solid cancers","volume":"35","author":"van de Haar","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Revista Espa\u00f1ola de Patolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699885526000188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699885526000188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:37:44Z","timestamp":1787312264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699885526000188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1699885526000188"],"URL":"https:\/\/doi.org\/10.1016\/j.patol.2026.100873","relation":{},"ISSN":["1699-8855"],"issn-type":[{"value":"1699-8855","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Patolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.patol.2026.100873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Anatom\u00eda Patol\u00f3gica.","name":"copyright","label":"Copyright"}],"article-number":"100873"}}